Acelyrin, Inc. announced that it?s founder Shao-Lee Lin, M.D., Ph.D. has stepped down as Chief Executive Officer and that Mina Kim, Chief Legal and Administrative officer at ACELYRIN, has been appointed Chief Executive Officer and to the company?s Board of Directors (the ?Board?). Ms. Kim brings more than 20 years of operational and leadership experience across a range of industries including synthetic biology, immunotherapy, renewable energy, and aviation. Ms. Kim played a pivotal role in ACELYRIN?s initial public offering and has served as ACELYRIN?s Chief Legal and Administrative Officer since November 2022.

Prior to that, she served as Chief Legal Officer and Head of Corporate Development at Zymergen, Inc., where she led the company?s corporate strategy and business development teams and built its legal team. She also oversaw Zymergen?s 2021 IPO process and the company?s eventual sale to Ginkgo Bioworks.